All News
Vitamin D Headlines (5.9.2025)
Dr. Jack Cush reviews the news, journal reports and lupus highlights from the past week on RheumNow.com. Triple positivity, the gut and CRPS, and hope for better outcomes with Vitamin D therapy.
Read Article
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
Opioid Deaths are Down (2.28.2025)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Opioid deaths are down, IL-33 levels are up and Weight loss is in the news again this week!
Read Article
Misdiagnosis of Dermatomyositis
JAMA Dermatology reports a retrospective cohort study from Johns Hopkins reviewing mimic of dermatomyositis (DM), suggesting that DM and especially clinically amyopathic DM (CADM) are commonly and initially misdiagnosed as inflammatory skin disease (ISD).
Read Article
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality.
Valentine RNL 2025 Review (2.14.2025)
Dr. Jack Cush reviews highlights from RheumNow Live 2025 held in Dallas, TX on Feb. 8-9, 2025.
Read Article
#EULAR2025 Abstr#OP0002 Promising new mode of action therapy for #myositis. Phase 2 RCT of efgartigimod (FcRn-i; coformulated with recombinant PH20) showed improvement in TIS & other key endpoints vs PBO at Wk24. Injection reaction common (23%). Will proceed to Phase 3 @RheumNow https://t.co/SuMolfcDkS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Retrospective multicentre study of 122 anti-synthetase syndrome pts - 14 (11%) had cancer associated myositis (CAM). The CAM SIR= 5.4 (elevated vs gen. pop. p < 0.0001). These pts were older, often +Hx cancer, lower CK levels, less weakness, worse survival. CAM cluster= older https://t.co/nuKg3P89a8
Dr. John Cush RheumNow ( View Tweet)
International Myositis Assessment and Clinical Studies Group (IMACS) reached a consensus on ‘anti-synthetase syndrome’ as the preferred nomenclature and "ASyS" as the preferred abbreviation for the ‘anti-synthetase syndrome. https://t.co/TuTzVVZzZO https://t.co/qs5f1qATKi
Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/re73lh2Xfs
Dr. John Cush RheumNow ( View Tweet)
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/Oi91niMn5M
Dr. John Cush RheumNow ( View Tweet)
Immune Checkpoint Inhib causing Myasthenia Gravis w/ poor outcomes - 16 ICI Rx pts (9 Lung CA, 7 other tumors) Dx w/ MG; 11 w/ overlap myositis. Mean onset @ 49d. All Rx wp steroids, 6 immunosuppressives, 5 plasma exchange; only 2 complete resp. 6 deaths re: MG complications https://t.co/PUc6kIE7FW
Dr. John Cush RheumNow ( View Tweet)
Review of SARCOPENIA - a loss of muscle mass and function, with significant implications on physical performance. More common in RA, SSc, SpA, SLE, FM, myositis, and vasculitis https://t.co/tCXdoEn9xR https://t.co/PvtmVCv2QJ
Dr. John Cush RheumNow ( View Tweet)
An Unusual Consult for Myopathy
Presentation by Dr. Kelsey Lemmen, at the Rheumatology Winter Clinical Symposia - Feb 2025
https://t.co/DYlzee6qcs https://t.co/nUxTC9roF9
Dr. John Cush RheumNow ( View Tweet)
FDA grants priority reviews to:
- Nicalizumab (J&J; FcRn antibody) for use in Myasthenia gravis.
- Upadacitinib (AbbVie; JAK inhib) for use in GCA
- Namistat (BI: PDE4B inhib) for use in Idiopathic pulmonary fibrosis
- Inalizumab (Hansen; anti-CD19) for use in IG4 rel Dz
-… https://t.co/dsg9vZASrk https://t.co/8t2USASmm8
Dr. John Cush RheumNow ( View Tweet)
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next?
- chest CT w/ myositis-specific autoAb panel
- dsDNA
- SCL-70 & Centromere Abs
- muscle biopsy https://t.co/t0WCIMtZg2 https://t.co/M1jBhnclLl
Dr. John Cush RheumNow ( View Tweet)
JAMA Case: A Woman With Painful Digital Ulcers - What would you order next?
- chest CT w/ myositis-specific autoAb panel
- dsDNA
- SCL-70 & Centromere Abs
- muscle biopsy https://t.co/9T8mNDdJTs https://t.co/pTphzcuZKF
Dr. John Cush RheumNow ( View Tweet)
Risk Prediction Modeling in MDA5 Dermatomyositis
Patients with Melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) are complicated and prone to interstitial lung disease, poor prognosis, and a high mortality. A new study suggests a risk prediction… https://t.co/v20ZCVZUQE https://t.co/GmWWQDpWUU
Dr. John Cush RheumNow ( View Tweet)
Facing challenges in diagnosing idiopathic inflammatory myopathies? Check out our recent webinar to hear from Stanley J. Naides, MD, FACP, FACR, as he explores the role of autoantibody testing in autoimmune myositis diagnosis and phenotyping. Sponsored by LabCorp Rx. #Myositis… https://t.co/4jMevolO3k https://t.co/ObWPR8QFW2
Dr. John Cush RheumNow ( View Tweet)
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush RheumNow ( View Tweet)
